Network pharmacology explores the potential mechanism of Salvia miltiorrhiza in the treatment of coronary heart disease complicated with depression or anxiety disorder / 西安交通大学学报(医学版)

ABSTRACT

【Objective】 To explore the potential mechanism of Salvia miltiorrhiza and its active monomers in patients with coronary heart disease （CHD） complicated with depression or anxiety disorder based on network pharmacology. 【Methods】 We collected the clinical data of 147 patients with CHD admitted to our hospital from March to April 2021 and investigated biochemical examination， drug treatment and the use of Chinese herbal compound. The downstream targets of active monomers of Salvia miltiorrhiza were screened based on TCMSP， PubChem and SwissTargetPrediction databases， and depression or anxiety-related genes were mining in OMIM， GeneCards and TTD databases. Protein-protein interaction network and GO and KEGG gene enrichment analyses were performed by matching Chinese herbal compound with disease targets. Chinese herbal compound-target-disease network was built by Cytoscape. 【Results】 Shuxuening （44.9%）， Salviae miltiorrhiza （27.9%）， and Sofren injection （21.8%） were the most commonly used Chinese herbal or injections in the clinical treatment of CHD， and there was no difference in the frequency of use between genders. Network pharmacology showed that the active components of Salvia miltiorrhiza might act on neuroactive ligand-receptor binding， 5-hydroxytryptamine synapses and dopaminergic synapses and participate in the regulation of neurotransmitter transport， dopamine and catecholamine metabolism and stress response. Target-disease network analysis showed that many active components of Salvia miltiorrhiza interacted with catechol-O-methyltransferase， monoamine oxidase， 5-hydroxytryptamine receptor and opioid receptor， which may be the potential targets of Salvia miltiorrhiza in improving depression and anxiety. 【Conclusion】 Salvia miltiorrhiza is involved in the regulation of neurotransmitters and synaptic activities， thus making it a potential drug for the clinical treatment of CHD complicated with depression and anxiety disorder.